Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etirinotecan Pegol in Relapsed Small Cell Lung Cancer
NCT01876446Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Aug 2013
- Primary completion
- Jul 2017
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etirinotecan pegol in small cell lung cancer (SCLC), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: 18 Week Progression-free Survival Rate. Started Aug 2013; status: completed.
02
Drugs
etirinotecan pegol
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT01876446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01876446.